17,261 trials
B-cell Lymphoma · Indolent B-cell Lymphoma
Primary: Determine Complete Response Rate (CRR) of Increased Dose Rituximab in Indolent B-cell Lymphomas — 21 Participants
Chronic Obstructive Pulmonary Disease
Primary: FEV1 AUC0-12 on Day 29 — 0.231; 0.197; 0.205; 0.011 Liters
Breast Cancer
Primary: Number of Participants With Response — 0 Participants
Liver Cancer
Primary: Disease Response Rate — 12.5 percentage of participants with response
Acute ST Elevation Myocardial Infarction
Primary: Infarct Size in the Territory of the Infarct Related Artery — 15.8; 15.0 percentage of LV mass
Diabetes Mellitus Type 2 · Non-alcoholic Fatty Liver Disease · Obesity
Primary: Difference in Hemoglobin A1c Values — 7.77; 7.68; 7.76; 7.44 percentage of hemoglobin glycated — p=0.05
Heat Stroke
Primary: Number of Subjects Achieving Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) GCS ≥ 13 — 5; 2 Participants — p=0.396
Delirium · Agitation
Primary: Resolution of Delirium — 21; 14 Participants
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) to LDK378 Per Investigator Assessment — 40.7 Percentage of participants
Leukemia · Lymphoma · Multiple Myeloma and Plasma Cell Neoplasm
Primary: Number of Patients With Day 100 Transplant-related Mortality — 1 Participants
Pancreatic Cancer
Primary: Overall Survival at 2 Years — 0.54 proportion of patients
Osteoarthritis of the Knee
Primary: Change in Synovitis — 9.8 units on a scale
Follicular Lymphoma · Marginal Zone Lymphoma · Mantle Cell Lymphoma
Primary: All Phase I-II Participants: Overall Response Rate (ORR) — 28 percentage of participants
Brain and Central Nervous System Tumors
Primary: Overall Survival — 15.6; 19.3 Months — p=.222
Lung Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Number of Patients Experiencing a DLT — 0; 1; 0; 0 Participants